A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics

Journal of Proteomics

Volumn 145, Issue , 2016, Pages 226-236

  Poersch, Aline ^a,b   Grassi, Mariana Lopes ^a,b   Carvalho, Vinícius Pereira de ^a   Lanfredi, Guilherme Pauperio ^a   Palma, Camila de Souza ^a,b   Greene, Lewis Joel ^a,b   de Sousa, Christiani Bisinoto ^a   Carrara, Hélio Humberto Angotti ^a   Candido dos Reis, Francisco José ^a   Faça, Vitor Marcel ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Regional Blood Center of Ribeirão Preto   (Brazil)

Author keywords

Biomarkers; Highthroughput proteomics; Multiple reactions monitoring (MRM); Ovarian cancer; Tumor fluid

Indexed keywords

ACUTE PHASE PROTEIN; ADAM17 PROTEIN; ALPHA 2 ANTIPLASMIN; APOLIPOPROTEIN E; HERMES ANTIGEN; OVIDUCT SPECIFIC GLYCOPROTEIN; PROTEASE C1 INHIBITOR; SERINE PROTEINASE INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG; TUMOR PROTEIN;

ABORTION; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYSTADENOMA; EARLY MENOPAUSE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING; ADULT; AGED; BODY FLUID; CHEMISTRY; EARLY CANCER DIAGNOSIS; HIGH THROUGHPUT SCREENING; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROCEDURES; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; BIOMARKERS, TUMOR; BODY FLUIDS; EARLY DETECTION OF CANCER; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEOMICS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84990955201     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2016.05.005     Document Type: Article

References (76)

1. [1] Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127 (2010), 2893–2917.
2. [2] Romero, I., Bast, R.C. Jr., Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology 153 (2012), 1593–1602.
3. [3] Yurkovetsky, Z., Skates, S., Lomakin, A., Nolen, B., Pulsipher, T., Modugno, F., et al. Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol. 28 (2010), 2159–2166.
4. [4] Mhawech-Fauceglia, P., Afkhami, M., Pejovic, T., MET/HGF signaling pathway in ovarian carcinoma: clinical implications and future direction. Pathol. Res. Int., 2012, 2012, 960327.
5. [5] Modugno, F., Laskey, R., Smith, A.L., Andersen, C.L., Haluska, P., Oesterreich, S., Hormone response in ovarian cancer: time to reconsider as a clinical target?. Endocr. Relat. Cancer 19 (2012), R255–R279.
6. [6] Jelovac, D., Armstrong, D.K., Role of farletuzumab in epithelial ovarian carcinoma. Curr. Pharm. Des. 18 (2012), 3812–3815.
7. [7] Ledermann, J.A., Raja, F.A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., Sessa, C., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24:Suppl. 6 (2013), vi24–vi32.
8. [8] Smolle, E., Taucher, V., Pichler, M., Petru, E., Lax, S., Haybaeck, J., Targeting signaling pathways in epithelial ovarian cancer. Int. J. Mol. Sci. 14 (2013), 9536–9555.
9. [9] Su, Z., Graybill, W.S., Zhu, Y., Detection and monitoring of ovarian cancer. Clin. Chim. Acta 415 (2013), 341–345.
10. [10] Poersch, A., Sousa, L.O., Greene, L.J., Faça, V.M., Candido dos Reis, F.J., Proteomic analysis of ovarian cancer tumor fluid is a rich source of potential biomarkers. J. Proteomics Bioinform. S 5 (2014), 1–9.
11. [11] Sturgeon, C.M., Hoffman, B.R., Chan, D.W., Ch'ng, S.L., Hammond, E., Hayes, D.F., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin. Chem. 54 (2008), e1–e10.
12. [12] Diamandis, E.P., Tumor markers: Past, present, and future. Diamandis, E.P., FH, J., L, H., C, D., S, M., (eds.) Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications, 2002, AACC Press, Washington DC, 3–8.
13. [13] Kristjansdottir, B., Partheen, K., Fung, E.T., Marcickiewicz, J., Yip, C., Brannstrom, M., et al. Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers. Clin. Proteomics, 9, 2012, 14.
14. [14] Kristjansdottir, B., Levan, K., Partheen, K., Carlsohn, E., Sundfeldt, K., Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ. Clin. Proteomics, 10, 2013, 4.
15. [15] Kristjansdottir, B., Partheen, K., Fung, E.T., Yip, C., Levan, K., Sundfeldt, K., Early inflammatory response in epithelial ovarian tumor cyst fluids. Cancer Med. 3 (2014), 1302–1312.
16. [16] Elzek, M.A., Rodland, K.D., Proteomics of ovarian cancer: functional insights and clinical applications. Cancer Metastasis Rev., 2015.
17. [17] Longuespee, R., Boyon, C., Desmons, A., Vinatier, D., Leblanc, E., Farre, I., et al. Ovarian cancer molecular pathology. Cancer Metastasis Rev. 31 (2012), 713–732.
18. [18] Zhang, Y., Xu, B., Liu, Y., Yao, H., Lu, N., Li, B., et al. The ovarian cancer-derived secretory/releasing proteome: a repertoire of tumor markers. Proteomics 12 (2012), 1883–1891.
19. [19] Cheng, Y., Liu, C., Zhang, N., Wang, S., Zhang, Z., Proteomics analysis for finding serum markers of ovarian cancer. Biomed. Res. Int., 2014, 2014, 179040.
20. [20] Timms, J.F., Arslan-Low, E., Kabir, M., Worthington, J., Camuzeaux, S., Sinclair, J., et al. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. Proteomics Clin. Appl. 8 (2014), 982–993.
21. [21] Sauer, S., Protein set analyses: how could this impact the clinic?. Expert Rev. Proteomics 10 (2013), 305–307.
22. [22] Faca, V., Coram, M., Phanstiel, D., Glukhova, V., Zhang, Q., Fitzgibbon, M., et al. Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J. Proteome Res. 5 (2006), 2009–2018.
23. [23] Rauch, A., Bellew, M., Eng, J., Fitzgibbon, M., Holzman, T., Hussey, P., et al. Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J. Proteome Res. 5 (2006), 112–121.
24. [24] MacLean, B., Eng, J.K., Beavis, R.C., McIntosh, M., General framework for developing and evaluating database scoring algorithms using the TANDEM search engine. Bioinformatics 22 (2006), 2830–2832.
25. [25] Nesvizhskii, A.I., Keller, A., Kolker, E., Aebersold, R., A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75 (2003), 4646–4658.
26. [26] Keller, A., Nesvizhskii, A.I., Kolker, E., Aebersold, R., Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74 (2002), 5383–5392.
27. [27] Muthusamy, B., Hanumanthu, G., Suresh, S., Rekha, B., Srinivas, D., Karthick, L., et al. Plasma Proteome Database as a resource for proteomics research. Proteomics 5 (2005), 3531–3536.
28. [28] Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43 (2015), D447–D452.
29. [29] Mi, H., Muruganujan, A., Thomas, P.D., PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 41 (2013), D377–D386.
30. [30] Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13 (2003), 2498–2504.
31. [31] MacLean, B., Tomazela, D.M., Shulman, N., Chambers, M., Finney, G.L., Frewen, B., et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26 (2010), 966–968.
32. [32] Mungenast, F., Thalhammer, T., Estrogen biosynthesis and action in ovarian cancer. Front. Endocrinol., 5, 2014, 192.
33. [33] Cantor, J.R., Sabatini, D.M., Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2 (2012), 881–898.
34. [34] Tennant, D.A., Duran, R.V., Gottlieb, E., Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10 (2010), 267–277.
35. [35] Ahmad, J., Hasnain, S.E., Siddiqui, M.A., Ahamed, M., Musarrat, J., Al-Khedhairy, A.A., MicroRNA in carcinogenesis & cancer diagnostics: a new paradigm. Indian J. Med. Res. 137 (2013), 680–694.
36. [36] Wang, L., Zhu, M.J., Ren, A.M., Wu, H.F., Han, W.M., Tan, R.Y., et al. A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. PLoS One, 9, 2014, e96472.
37. [37] Ma, J., Mannoor, K., Gao, L., Tan, A., Guarnera, M.A., Zhan, M., et al. Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing. Mol. Oncol. 8 (2014), 1208–1219.
38. [38] Berillo, O., Regnier, M., Ivashchenko, A., Binding of intronic miRNAs to the mRNAs of host genes encoding intronic miRNAs and proteins that participate in tumourigenesis. Comput. Biol. Med. 43 (2013), 1374–1381.
39. [39] Swarbrick, A., Woods, S.L., Shaw, A., Balakrishnan, A., Phua, Y., Nguyen, A., et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat. Med. 16 (2010), 1134–1140.
40. [40] Voellenkle, C., Rooij, J., Guffanti, A., Brini, E., Fasanaro, P., Isaia, E., et al. Deep-sequencing of endothelial cells exposed to hypoxia reveals the complexity of known and novel microRNAs. RNA 18 (2012), 472–484.
41. [41] Aad, G., Abajyan, T., Abbott, B., Abdallah, J., Abdel Khalek, S., Abdelalim, A.A., et al. Search for magnetic monopoles in sqrt[s] = 7 TeV pp collisions with the ATLAS detector. Phys. Rev. Lett., 109, 2012, 261803.
42. [42] Hanash, S.M., Pitteri, S.J., Faca, V.M., Mining the plasma proteome for cancer biomarkers. Nature 452 (2008), 571–579.
43. [43] Eichner, J.E., Dunn, S.T., Perveen, G., Thompson, D.M., Stewart, K.E., Stroehla, B.C., Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 155 (2002), 487–495.
44. [44] Mahley, R.W., Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240 (1988), 622–630.
45. [45] Song, Y., Stampfer, M.J., Liu, S., Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 141 (2004), 137–147.
46. [46] Gliemann, J., Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands. Biol. Chem. 379 (1998), 951–964.
47. [47] Ho, Y.Y., Deckelbaum, R.J., Chen, Y., Vogel, T., Talmage, D.A., Apolipoprotein E inhibits serum-stimulated cell proliferation and enhances serum-independent cell proliferation. J. Biol. Chem. 276 (2001), 43455–43462.
48. [48] Mahley, R.W., Rall, S.C. Jr., Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1 (2000), 507–537.
49. [49] Chen, Y.C., Pohl, G., Wang, T.L., Morin, P.J., Risberg, B., Kristensen, G.B., et al. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res. 65 (2005), 331–337.
50. [50] Collen, D., Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur. J. Biochem. 69 (1976), 209–216.
51. [51] Miles, L.A., Plow, E.F., Donnelly, K.J., Hougie, C., Griffin, J.H., A bleeding disorder due to deficiency of alpha 2-antiplasmin. Blood 59 (1982), 1246–1251.
52. [52] Carpenter, S.L., Mathew, P., Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 14 (2008), 1250–1254.
53. [53] Davis, A.E. 3rd, Lu, F., Mejia, P., C1 inhibitor, a multi-functional serine protease inhibitor. Thromb. Haemost. 104 (2010), 886–893.
54. [54] Pio, R., Ajona, D., Lambris, J.D., Complement inhibition in cancer therapy. Semin. Immunol. 25 (2013), 54–64.
55. [55] Buhi, W.C., Characterization and biological roles of oviduct-specific, oestrogen-dependent glycoprotein. Reproduction 123 (2002), 355–362.
56. [56] Woo, M.M., Gilks, C.B., Verhage, H.G., Longacre, T.A., Leung, P.C., Auersperg, N., Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts. Gynecol. Oncol. 93 (2004), 315–319.
57. [57] Richards, F.M., Tape, C.J., Jodrell, D.I., Murphy, G., Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS One, 7, 2012, e40597.
58. [58] Rosso, O., Piazza, T., Bongarzone, I., Rossello, A., Mezzanzanica, D., Canevari, S., et al. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol. Cancer Res. 5 (2007), 1246–1253.
59. [59] Santiago-Josefat, B., Esselens, C., Bech-Serra, J.J., Arribas, J., Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors. J. Biol. Chem. 282 (2007), 8325–8331.
60. [60] Lin, P., Sun, X., Feng, T., Zou, H., Jiang, Y., Liu, Z., et al. ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway. Mol. Cell. Biochem. 359 (2012), 235–243.
61. [61] Maretzky, T., Evers, A., Zhou, W., Swendeman, S.L., Wong, P.M., Rafii, S., et al. Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nat. Commun., 2, 2011, 229.
62. [62] Van Schaeybroeck, S., Kyula, J.N., Fenton, A., Fenning, C.S., Sasazuki, T., Shirasawa, S., et al. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. Cancer Res. 71 (2011), 1071–1080.
63. [63] Gijsen, M., King, P., Perera, T., Parker, P.J., Harris, A.L., Larijani, B., et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol., 8, 2010, e1000563.
64. [64] Cho, E.Y., Choi, Y., Chae, S.W., Sohn, J.H., Ahn, G.H., Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol. Int. 56 (2006), 62–70.
65. [65] Preca, B.T., Bajdak, K., Mock, K., Sundararajan, V., Pfannstiel, J., Maurer, J., et al. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells. Int. J. Cancer 137 (2015), 2566–2577.
66. [66] Sacks, J.D., Barbolina, M.V., Expression and function of CD44 in epithelial ovarian carcinoma. Biomolecules 5 (2015), 3051–3066.
67. [67] Sillanpaa, S., Anttila, M.A., Voutilainen, K., Tammi, R.H., Tammi, M.I., Saarikoski, S.V., et al. CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin. Cancer Res. 9 (2003), 5318–5324.
68. [68] Cannistra, S.A., Abu-Jawdeh, G., Niloff, J., Strobel, T., Swanson, L., Andersen, J., et al. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J. Clin. Oncol. 13 (1995), 1912–1921.
69. [69] Ferraro, S., Schiumarini, D., Panteghini, M., Human epididymis protein 4: factors of variation. Clin. Chim. Acta 438 (2015), 171–177.
70. [70] Luo, J., Song, J., Feng, P., Wang, Y., Long, W., Liu, M., et al. Elevated serum apolipoprotein E is associated with metastasis and poor prognosis of non-small cell lung cancer. Tumour Biol., 2016.
71. [71] Rice, S.J., Liu, X., Miller, B., Joshi, M., Zhu, J., Caruso, C., et al. Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung. Proteomics 15 (2015), 3267–3277.
72. [72] Cooper, D.L., Tumor markers. Goldman, L., Bennett, J.C., (eds.) Cecil Textbook of Medicine, 22nd ed., 2004, WB Saunders Company, Philadelphia.
73. [73] Sokoll, L.J., Chan, D.W., Clinical chemistry: tumor markers. Abeloff, M.D., Armitage, J.O., Niederhuber, J.E., Kastan, M.B., McKenna, W.G., (eds.) Abeloff: Clinical Oncology, third ed., 2004, Elsevier Churchill Livingston, Pennsylvania.
74. [74] Basuyau, J.P., Leroy, M., Brunelle, P., Determination of tumor markers in serum. Pitfalls and good practice. Clin. Chem. Lab. Med. 39 (2001), 1227–1233.
75. [75] Bast, R.C. Jr., Knauf, S., Epenetos, A., Dhokia, B., Daly, L., Tanner, M., et al. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 68 (1991), 1758–1763.
76. [76] Wu, J.T., Expression of monoclonal antibody-defined tumor markers in four carcinomas. Ann. Clin. Lab. Sci. 19 (1989), 17–26.